World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
22655
World Ranking
19076
National Ranking
9509

Overview

C. Patrick Reynolds is affiliated with Texas Tech University Health Sciences Center in the United States. Their research spans multiple areas within medicine and molecular biology, focusing significantly on neuroblastoma and cancer biology. Reynolds has contributed extensively to the understanding of cancer mechanisms, telomere biology, and therapeutic resistance in cancer cells.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broad fields, Reynolds has concentrated research efforts on the following subfields:

  • Molecular Biology
  • Neurology
  • Oncology
  • Cancer Research
  • Ophthalmology

Key topics investigated by Reynolds cover a range of cancer-related areas:

  • Neuroblastoma Research and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Cancer therapeutics and mechanisms
  • Telomeres, Telomerase, and Senescence
  • Cell death mechanisms and regulation
  • Glioma Diagnosis and Treatment
  • Cancer-related Molecular Pathways

Recent notable publications authored or co-authored by Reynolds include:

  • "Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma" (2020, Cancer Research)
  • "ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156" (2021, Science Translational Medicine)
  • "MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma" (2020, Cell Death and Disease)
  • "Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance" (2022, The EMBO Journal)
  • "Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function" (2022, Cancer Research)

Reynolds frequently publishes in a select group of venues, reflecting their focus on oncology and clinical research:

  • Cancer Research
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Science Translational Medicine
  • Cancer Chemotherapy and Pharmacology

The scientist has collaborated regularly with multiple co-authors, suggesting ongoing partnerships in their research work. Frequent collaborators include:

  • Balakrishna Koneru
  • Min H. Kang
  • Trevor A. Burrow
  • Ashly Hindle
  • Thinh H. Nguyen

Best Publications

  • Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

    Alice L. Yu;Andrew L. Gilman;M. Fevzi Ozkaynak;Wendy B. London

  • Determination of subcutaneous tumor size in athymic (nude) mice

    Mary M. Tomayko;C. Patrick Reynolds

  • Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.

    Min H. Kang;C. Patrick Reynolds

  • Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

    Katherine K. Matthay;C. Patrick Reynolds;Robert C. Seeger;Hiroyuki Shimada

  • The pediatric preclinical testing program: description of models and early testing results.

    Peter J. Houghton;Christopher L. Morton;Chandra Tucker;Debbie Payne

  • Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.

    Mark Sausen;Rebecca J Leary;Siân Jones;Siân Jones;Jian Wu;Jian Wu

  • Ceramide synthesis and metabolism as a target for cancer therapy.

    C.Patrick Reynolds;Barry J. Maurer;Richard N. Kolesnick

  • Retinoid therapy of high-risk neuroblastoma.

    C.Patrick Reynolds;Katherine K. Matthay;Judith G. Villablanca;Barry J. Maurer

  • Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma

    David L. Baker;Mary L. Schmidt;Susan L. Cohn;John M. Maris

  • The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA

    Philipp Kapranov;Georges St Laurent;Georges St Laurent;Tal Raz;Fatih Ozsolak

  • Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

    Suzanne S. Shusterman;Wendy B. London;Stephen D. Gillies;Jacquelyn A. Hank

  • Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial

    Susan G Kreissman;Robert C Seeger;Katherine K Matthay;Wendy B London;Wendy B London

  • Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

    John M. Maris;John M. Maris;Christopher L. Morton;Richard Gorlick;E. Anders Kolb

  • Synergistic Cytotoxicity in Solid Tumor Cell Lines Between N-(4-Hydroxyphenyl)retinamide and Modulators of Ceramide Metabolism

    Barry J. Maurer;Lisa Melton;Carolyn Billups;Myles C. Cabot

  • E-Cadherin Cell-Cell Adhesion in Ewing Tumor Cells Mediates Suppression of Anoikis through Activation of the ErbB4 Tyrosine Kinase

    Hyung-Gyoo Kang;Jasmine M. Jenabi;Jingsong Zhang;Nino Keshelava

  • A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children’s Oncology Group

    Kaci L. Osenga;Jacquelyn A. Hank;Mark R. Albertini;Jacek Gan

  • Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641

    Douglas R. Strother;Wendy B. London;Mary Lou Schmidt;Garrett M. Brodeur

  • Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.

    E. Anders Kolb;E. Anders Kolb;Richard Gorlick;Peter J. Houghton;Christopher L. Morton

  • Phase I Dose Escalation of Iodine-131–Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study

    Katherine K. Matthay;Jessica C. Tan;Judith G. Villablanca;Gregory A. Yanik

  • Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

    Peter J. Houghton;Christopher L. Morton;E. Anders Kolb;Richard Gorlick

Frequent Co-Authors

John M. Maris
John M. Maris Children's Hospital of Philadelphia
Malcolm A. Smith
Malcolm A. Smith National Institutes of Health
Peter J. Houghton
Peter J. Houghton The University of Texas Health Science Center at San Antonio
Richard Gorlick
Richard Gorlick The University of Texas MD Anderson Cancer Center
Robert C. Seeger
Robert C. Seeger Children's Hospital of Los Angeles
Timothy J. Triche
Timothy J. Triche Van Andel Institute
Katherine K. Matthay
Katherine K. Matthay University of California, San Francisco
Susan Groshen
Susan Groshen University of Southern California
Hiroyuki Shimada
Hiroyuki Shimada Stanford University
Wendy B. London
Wendy B. London Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative career pathways in healthcare can expand your options beyond traditional medical school. For those looking to enter the workforce quickly, accelerated lpn programs offer a fast and flexible entry point into nursing, equipping you with hands-on patient care experience in as little as a year.

If mental health interests you, there are accelerated msn psychiatric np programs available online. These programs let registered nurses move quickly into advanced practice roles focused on psychiatric and mental health care—an area with growing demand.

There’s also strong demand for leadership in the healthcare sector. Earning a healthcare administration degree online can prepare you for administrative and management roles, influencing how care is delivered across health systems.

For further career advancement, consider the options for a master’s in this field. Find programs with a manageable investment by comparing masters in healthcare administration cost to optimize both your education and financial planning.

Best Scientists Citing C. Patrick Reynolds

Trending Scientists

Recently Published Articles